LifeStance Health Group, Inc. Form 8-K Summary
Business context and reporting period
LifeStance Health Group, Inc. filed a Current Report on Form 8-K dated November 2, 2022, with the report signed November 3, 2022. The filing concerns executive leadership and compensation matters; it does not report quarterly or annual operating results.
Financial metrics and liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating performance metrics.
Material changes versus the prior comparable period
- David Bourdon was appointed Chief Financial Officer and Treasurer effective November 10, 2022.
- J. Michael Bruff ceased serving as Chief Financial Officer and Treasurer and transitioned to leader of the Business Transformation office.
- The filing does not provide a comparable-period financial statement or quantified operating-performance comparison.
Compensation, outlook, risks, and unusual items
- Mr. Bourdon’s employment agreement provides for a $500,000 annual base salary and, beginning in 2023, a target annual bonus equal to 75% of base salary, subject to performance objectives.
- He will receive a one-time $1.0 million signing bonus payable in company shares. The bonus is generally subject to repayment if employment ends before the fourth anniversary, except in specified circumstances.
- Mr. Bourdon will receive an option to purchase 1,250,000 shares under the 2021 Equity Incentive Plan. One-third is subject to time-based vesting and two-thirds to time- and performance-based vesting.
- Specified terminations may trigger 12 months of salary continuation and certain insurance benefits. Additional change-in-control protections may apply, without duplication.
- Under transition arrangements, Mr. Bruff’s specified time-based equity awards scheduled to vest through March 8, 2023 and April 1, 2023 will vest in full on the effective date.
- Mr. Bruff will not repay $1.5 million of his sign-on bonus, will surrender approximately $1.0 million of company shares toward the remaining repayment obligation, and will not repay his relocation payment.
- The arrangements include confidentiality, invention-assignment, and 18-month noncompetition and nonsolicitation covenants, as well as release-of-claims conditions.
Important facts for investors to verify
- Review the full employment, equity award, and transition agreements when filed with the company’s 2022 Form 10-K.
- Assess the potential dilution and expense associated with the 1,250,000-share option and the signing bonus payable in shares.
- Monitor future disclosures for cash or equity costs, vesting outcomes, severance obligations, and change-in-control liabilities.
- Confirm the effective date and responsibilities of the new CFO and the impact of the Business Transformation office transition.